OverviewSuggest Edit

Spotlight Innovation is a pharmaceutical company. It focuses on acquiring rights to innovative and proprietary therapeutics designed to address unmet medical needs. The Company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; STL-182, an orally-available small molecule for the treatment of spinal muscular atrophy; and products derived from cobra and venom to treat chronic pain. Spotlight Innovation offers SOLX Gold Shunt, an implantable drainage device designed to reduce elevated intraocular pressure associated with refractory glaucoma without creating a bleb.
TypePublic
Founded2006
HQUrbandale, US
Websitespotlightinnovation.com

Latest Updates

Employees (est.) (Feb 2019)4(+100%)
Revenue (FY, 2017)$2.2 K
Share Price (Oct 2017)$0.1

Key People/Management at Spotlight Innovation

Chitra Edwin

Chitra Edwin

Senior Vice President of Regulatory Affairs and Compliance
Paul Reid

Paul Reid

President, Celtic Biotech Iowa, Inc.
Show more

Spotlight Innovation Office Locations

Spotlight Innovation has an office in Urbandale
Urbandale, US (HQ)
11165 Aurora Ave
Show all (1)

Spotlight Innovation Financials and Metrics

Spotlight Innovation Revenue

Spotlight Innovation's revenue was reported to be $2.23 k in FY, 2017
USD

Revenue (Q2, 2018)

2.2k

Gross profit (Q2, 2018)

735.0

Gross profit margin (Q2, 2018), %

32.9%

Net income (Q2, 2018)

(1.0m)

EBIT (Q2, 2018)

(745.9k)

Market capitalization (31-Oct-2017)

3.3m

Closing stock price (31-Oct-2017)

0.1

Cash (30-Jun-2018)

2.0k

EV

3.6m
Spotlight Innovation's current market capitalization is $3.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.2k

Cost of goods sold

126.7k

Gross profit

(124.5k)

Gross profit Margin, %

(5593%)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

910.014.5k2.2k

Cost of goods sold

52.9k68.2k1.9k2.9k1.5k

Gross profit

(1.0k)11.6k735.0

Gross profit Margin, %

(114%)80%33%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

16.5k4.5k19.1k9.1k299.9k313.3k66.1k

Prepaid Expenses

17.5k214.5k4.0k

Inventories

192.7k

Current Assets

16.5k145.9k131.3k317.4k1.5m262.9k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

16.9k15.2k5.5k6.4k5.0k4.0k4.3k4.3k245.02.0k2.0k1.6m1.0m541.0k266.0k72.5k289.3k223.9k127.8k150.6k39.6k2.0k

Accounts Receivable

999.0360.0

Prepaid Expenses

35.0k26.3k8.8k3.1k117.0k188.0k241.9k8.6k10.0k1.8k

Inventories

145.4k145.4k197.4k191.1k189.8k
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(4.5m)(600.0k)(6.8m)(3.6m)(8.1m)(16.8m)(6.5m)

Depreciation and Amortization

3.0k1.4k525.03.0k4.7k4.9k

Inventories

(4.4k)

Accounts Payable

3.4k21.3k34.7k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(421.8k)(585.2k)(150.6k)(309.9k)(462.1k)(141.4k)(308.0k)(556.4k)(112.9k)(1.3m)(2.0m)(961.3k)(2.0m)(4.1m)(1.5m)(2.6m)(4.6m)(2.2m)(3.8m)(5.7m)(983.4k)(2.0m)

Depreciation and Amortization

1.7k2.5k300.0225.0878.01.6k1.6k3.2k4.9k1.3k2.6k3.8k1.1k1.9k

Inventories

(1.7k)(2.9k)

Accounts Payable

(9.6k)1.0k5.6k31.3k18.1k8.6k47.9k123.6k23.0k45.9k
USDY, 2018

EV/EBIT

-4.9 x

EV/CFO

-3.1 x

Debt/Equity

-0.3 x

Financial Leverage

-6.2 x
Show all financial metrics

Spotlight Innovation Online and Social Media Presence

Embed Graph

Spotlight Innovation Blogs

Spotlight Innovation Spinal Muscular Atrophy Research Collaborator Professor Kevin Hodgetts Receives $300,000 Grant from Cure SMA

URBANDALE, IA, July 24, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company research collaborator Professor Kevin Hodgetts has been awarded a grant of $300,000 by the nonprofit org…

Spotlight Innovation Frequently Asked Questions

  • When was Spotlight Innovation founded?

    Spotlight Innovation was founded in 2006.

  • Who are Spotlight Innovation key executives?

    Spotlight Innovation's key executives are Chitra Edwin and Paul Reid.

  • How many employees does Spotlight Innovation have?

    Spotlight Innovation has 4 employees.

  • What is Spotlight Innovation revenue?

    Latest Spotlight Innovation annual revenue is $2.2 k.

  • What is Spotlight Innovation revenue per employee?

    Latest Spotlight Innovation revenue per employee is $557 .

  • Who are Spotlight Innovation competitors?

    Competitors of Spotlight Innovation include Alnylam Pharmaceuticals, Antipodean Pharmaceuticals and Iterum Therapeutics.

  • Where is Spotlight Innovation headquarters?

    Spotlight Innovation headquarters is located at 11165 Aurora Ave, Urbandale.

  • Where are Spotlight Innovation offices?

    Spotlight Innovation has an office in Urbandale.

  • How many offices does Spotlight Innovation have?

    Spotlight Innovation has 1 office.